Chronic Obstructive Pulmonary Disease (COPD), , secondary to smoking, is a major public health issue with very high direct and indirect costs. The impact on the health system of undiagnosed patients, up to 70% of patients, is increasingly documented. However, systematic spirometry screening remains controversial among smokers in the absence of data to link the detection of new patients with improved management and clinical events and health goals. More generally, there is little data on the evolution of patients in real life once they have entered the care system. The premise is that with systematic screening in general medicine, it is possible to identify the evolution of newly diagnosed COPD patients, to distinguish the different possible evolutions according to the initial phenotype and the management.
A description of the population from which the groups or cohorts will be selected Smokers who have a screening spirometry for COPD, either in general medicine, at a pulmonologist or in the CHIC or Henri Mondor hospital respiratory function tests department. After screening, an equal number of men and women COPD will be included (150 men and 150 women). 1500 smokers will be included to reach 300 smokers with COPD.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
300
* clinical investigations * imagery * blood assessment * functional respiratory investigations * muscle function / skeletal muscle index
Hopital Henri MONDOR
Créteil, Île-de-France Region, France
RECRUITING1-year adverse evolution
1-year adverse evolution defined by a composite criterion associating: \- Occurrence of an additional exacerbation defined by any event requiring the use of the care system (visit to the doctor, emergencies, or hospitalization, for respiratory aggravation) with prescription of antibiotics or systemic steroids AND/OR \- Increased dyspnea by 1 point on the MMRC dyspnea score AND/OR \- CAT\> 10 or 2 points increase on CAT symptom scores
Time frame: at 12 Months
Adverse evolution
\- Occurrence of an additional exacerbation defined by any event requiring the use of the care system (visit to the doctor, emergencies, or hospitalization, for respiratory aggravation) with prescription of antibiotics or systemic steroids AND/OR \- Increased dyspnea by 1 point on the MMRC dyspnea score AND/OR \- CAT\> 10 or 2 points increase on CAT symptom scores
Time frame: at 3 Months and 6 Months
Exacerbation
Occurrence of an additional exacerbation defined by any event requiring the use of the care system (visit to the doctor, emergencies, or hospitalization, for respiratory aggravation) with prescription of antibiotics or systemic steroids
Time frame: at 3 Months, 6 Months and 12 Months
Number of steps
Number of steps in the month preceding the visit evaluated by a pedometer
Time frame: at 3 Months, 6 Months and 12 Months
Forced Expiratory Volume in one second (FEV1)
Forced Expiratory Volume in one second (FEV1)
Time frame: at 3 Months, 6 Months and 12 Months
Hospital Anxiety and Depression scale
Anxious symptoms or depressions
Time frame: at 3 Months, 6 Months and 12 Months
FEV 1 / Respiratory function parameters
Respiratory function parameters with FEV 1
Time frame: at 12 Months
DLCO / Respiratory function parameters
Respiratory function parameters with DLCO
Time frame: at 12 Months
Residual volume / Respiratory function parameters
Respiratory function parameters with residual volume
Time frame: at 12 Months
Total lung capacity / Respiratory function parameters
Respiratory function parameters with total lung capacity
Time frame: at 12 Months
Arterial stiffness
Arterial stiffness measured by the pulse wave velocity (Complior)
Time frame: at 12 Months
LVEF / Echocardiography
LVEF measured by echocardiography
Time frame: at 12 Months
Diastolic dysfunction / Echocardiography
diastolic dysfunction measured by echocardiography
Time frame: at 12 Months
PAPS / Echocardiography
PAPS measured by echocardiography
Time frame: at 12 Months
Skeletal muscle index
Skeletal muscle index evaluated by IDEXA
Time frame: at 12 Months
Muscle function
Muscle strength by grip and pinch
Time frame: at 12 Months
Hospital Anxiety and Depression scale
Measurement of anxiety symptoms or depression via the Hospital Anxiety and Depression scale.
Time frame: at 12 Months
Numbers of deaths
Numbers of deaths
Time frame: at 12 Months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.